S
Samit Hirawat
Researcher at Novartis
Publications - 64
Citations - 7275
Samit Hirawat is an academic researcher from Novartis. The author has contributed to research in topics: Nonsense mutation & Cancer. The author has an hindex of 22, co-authored 64 publications receiving 5818 citations. Previous affiliations of Samit Hirawat include Bristol-Myers Squibb.
Papers
More filters
Journal ArticleDOI
Alpelisib for PIK3CA-Mutated, Hormone Receptor–Positive Advanced Breast Cancer
Fabrice Andre,Eva Ciruelos,G. Rubovszky,Mario Campone,Sibylle Loibl,Hope S. Rugo,H. Iwata,Pierfranco Conte,Ingrid A. Mayer,Bella Kaufman,Toshinari Yamashita,Yen-Shen Lu,Kenichi Inoue,Masato Takahashi,Zsuzsanna Papai,Anne-Sophie Longin,David Mills,Celine Wilke,Samit Hirawat,Dejan Juric +19 more
TL;DR: Treatment with alpelisib–fulvestrant prolonged progression‐free survival among patients with PIK3CA‐mutated, HR‐positive, HER2‐negative advanced breast cancer who had received endocrine therapy previously.
Journal ArticleDOI
Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer
Gabriel N. Hortobagyi,Salomon M. Stemmer,Howard A. Burris,Yoon Sim Yap,Gabe S. Sonke,Shani Paluch-Shimon,Mario Campone,Kimberly L. Blackwell,Fabrice Andre,Eric P. Winer,Wolfgang Janni,Sunil Verma,Pierfranco Conte,Carlos L. Arteaga,David Cameron,Katarína Petráková,Lowell L. Hart,Cristian Villanueva,A. Chan,Erik Jakobsen,Arnd Nusch,Olga Burdaeva,Eva-Maria Grischke,Emilio Alba,Erik Wist,Norbert Marschner,Anne Favret,Denise A. Yardley,Thomas Bachelot,Ling-Ming Tseng,Sibel Blau,Fengjuan Xuan,Farida Souami,Michelle Miller,C. Germa,Samit Hirawat,Joyce O'Shaughnessy +36 more
TL;DR: Among patients receiving initial systemic treatment for HR-positive, HER2-negative advanced breast cancer, the duration of progression-free survival was significantly longer among those receiving ribociclib plus letrozole than among those received placebo plus let rozole, with a higher rate of myelosuppression in the ribocIClib group.
Journal ArticleDOI
PTC124 targets genetic disorders caused by nonsense mutations
Ellen Welch,Elisabeth R. Barton,Jin Zhuo,Yuki Tomizawa,Westley J. Friesen,Panayiota Trifillis,Sergey Paushkin,Meenal Patel,Christopher R. Trotta,Seongwoo Hwang,Wilde Richard Gerald,Gary Mitchell Karp,James J. Takasugi,Guangming Chen,S. M. Jones,Hongyu Ren,Young-Choon Moon,Donald Thomas Corson,Anthony Turpoff,Jeffrey Allen Campbell,M. Morgan Conn,Atiyya Khan,Neil G. Almstead,Jean Hedrick,Anna Mollin,Nicole Risher,Marla Weetall,Shirley Yeh,Arthur Branstrom,Joseph M. Colacino,John Babiak,William D. Ju,Samit Hirawat,Valerie Northcutt,Langdon L. Miller,Phyllis Spatrick,Feng He,Masataka Kawana,Huisheng Feng,Allan Jacobson,Stuart W. Peltz,H. Lee Sweeney +41 more
TL;DR: The selectivity of PTC124 for premature termination codons, its well characterized activity profile, oral bioavailability and pharmacological properties indicate that this drug may have broad clinical potential for the treatment of a large group of genetic disorders with limited or no therapeutic options.
Journal ArticleDOI
Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial
Debu Tripathy,Seock-Ah Im,Marco Colleoni,Fabio Franke,Aditya Bardia,Nadia Harbeck,Sara A. Hurvitz,Louis W.C. Chow,Joohyuk Sohn,Keun Seok Lee,Saúl Campos-Gómez,Rafael Villanueva Vazquez,Kyung Hae Jung,K Govind Babu,Paul Wheatley-Price,Michelino De Laurentiis,Young-Hyuck Im,Sherko Kuemmel,Nagi S. El-Saghir,Mei Ching Liu,Gary Carlson,Gareth Hughes,I Diaz-Padilla,C. Germa,Samit Hirawat,Yen-Shen Lu +25 more
TL;DR: In this paper, ribociclib plus endocrine therapy showed improved progression-free survival compared with letrozole alone as first-line treatment for postmenopausal patients with hormone receptor (HR)-positive, HER2-negative, advanced breast cancer.
Journal ArticleDOI
Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial
Eitan Kerem,Samit Hirawat,S. Armoni,Yasmin Yaakov,David Shoseyov,Michael Cohen,Malka Nissim-Rafinia,H. Blau,Joseph Rivlin,Micha Aviram,Gary Elfring,Valerie Northcutt,Langdon L. Miller,Batsheva Kerem,Michael Wilschanski +14 more
TL;DR: In patients with cystic fibrosis who have a premature stop codon in the CFTR gene, oral administration of PTC124 to suppress nonsense mutations reduces the epithelial electrophysiological abnormalities caused by CFTR dysfunction.